## JNJ: Johnson & Johnson - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.12 indicates fundamental undervaluation. Quality metrics strong (ROE 34%). Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($197.77)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 2)

**1. J&J Stops Mid-stage Eczema Trial as $1.25B Asset Misses Efficacy Mark**
- Source: BioSpace | 20260105T132726 | Bearish | Relevance: 100%
- Johnson & Johnson has halted a Phase IIb trial for JNJ-95475939, a bispecific antibody for atopic dermatitis, after it failed to meet efficacy expectations in an interim analysis. J&J had paid Numab Therapeutics $1.25 billion upfront for the asset, which targeted IL-4 and IL-31. The company will now focus on other dermatology candidates, including assets acquired from Proteologix and a STAT6 program from Kaken Pharmaceutical.

**2. Johnson & Johnson stock today: JNJ’s $1.30 dividend sets key dates — what investors watch next**
- Source: ts2.tech | 20260103T192046 | Neutral | Relevance: 100%
- Johnson & Johnson has declared a quarterly cash dividend of $1.30 per share, payable March 10, with the ex-dividend date set for February 24. This announcement comes as JNJ shares closed up 0.2% at $207.35. Investors are now looking forward to the company's fourth-quarter earnings call on January 21 and the broader direction of interest rates.

**3. Johnson & Johnson Announces Quarterly Dividend for First Quarter 2026**
- Source: Investing News Network | 20260103T030829 | Bullish | Relevance: 100%
- Johnson & Johnson announced its Board of Directors has declared a cash dividend of $1.30 per share for the first quarter of 2026. The dividend is payable on March 10, 2026, to shareholders of record as of February 24, 2026, with the ex-dividend date also on February 24, 2026. This announcement highlights the company's commitment to returning value to its shareholders.

**4. Legal Bay Settlement Funding Reports Johnson & Johnson Hit with Almost $1 Billion in Trial Damages During Fourth Quarter of 2025**
- Source: PR Newswire | 20260105T180832 | Bearish | Relevance: 100%
- Legal Bay Settlement Funding reports that Johnson & Johnson faced nearly $1 billion in trial damages during the fourth quarter of 2025 due to lawsuits related to its talc-based products. Recent verdicts include $40 million to two women in California for ovarian cancer and $966 million in October 2025 for mesothelioma. These substantial jury awards are increasing pressure on Johnson & Johnson to resolve thousands of outstanding talc lawsuits nationally.

**5. Johnson & Johnson stock rating reiterated at Buy by UBS on strong fundamentals**
- Source: Investing.com | 20260105T160828 | Bullish | Relevance: 100%
- UBS has reiterated a Buy rating for Johnson & Johnson (NYSE:JNJ) while adjusting EPS estimates downward due to anticipated deal dilution. Despite this, the firm maintains a positive outlook, citing strong fundamentals, robust sales growth in innovative medicines, a healthy pipeline to offset STELARA declines, and resilience in its MedTech business. The company's long-term prospects are further supported by numerous new product launches and management's confidence in future performance.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 6, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-30 | Barclays | $217 | $197 | +10% |
| 2025-12-19 | Goldman Sachs | $240 | $213 | +13% |
| 2025-12-15 | B of A Securiti | $220 | $204 | +8% |
| 2025-12-12 | Morgan Stanley | $197 | $190 | +4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-30 | Barclays | main | Equal-Weight |
| 2025-12-19 | Goldman Sachs | main | Buy |
| 2025-12-15 | B of A Securiti | main | Neutral |
| 2025-12-12 | Morgan Stanley | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 5 ($3.81M) |
| Sells | 6 ($0.64M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 36.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 9.8% (-0.2%)
- Blackrock Inc.: 8.6% (+1.7%)
- State Street Corpora: 5.5% (-0.4%)
- JPMORGAN CHASE & CO: 4.9% (+109.0%)
- Geode Capital Manage: 2.3% (-7.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 6 raises (avg +9%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.12 suggests fair value with growth premium. Forward P/E 17.7x stretched relative to 6% growth. Quality metrics strong (ROE 34%, margin 27%). Balance sheet: $8.4B free cash flow. Analyst sentiment positive (6 raises, avg +9%). Insider buying signal ($3.8M), management confidence. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $492.2B |
| Beta | 0.33 |
| 52W Range | $140.68 - $215.19 |
| Short Interest | 1.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.12 |
| Forward P/E | 17.7 |
| Current P/E | 18.8 |
| YoY Growth | 6.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -0.0% to -1.5% (-1.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.5pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.17x) but short-term weakness (below SMA20). MACD histogram bearish (-0.83), momentum weakening. RSI neutral at 48. OFD pattern: -SLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.49% (CS: 24) | Neutral |
| RSI_14 | 47.6 | Neutral |
| MACD Histogram | -0.83 | Bearish |
| vs SMA20 | 0.987x | Below |
| vs SMA50 | 1.019x | Above |
| vs SMA200 | 1.172x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $204.31
- **Stop Loss:** $197.77 (3.2% risk)
- **Target:** $217.39 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 131
- **Position Value:** $26,764.61
- **Portfolio %:** 26.76%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-01-21 (Est: $2.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.76 | $2.80 | +1.5% |
| 2025Q2 | $2.68 | $2.77 | +3.2% |
| 2025Q1 | $2.58 | $2.77 | +7.4% |
| 2024Q4 | $2.01 | $2.04 | +1.4% |

---
*RULE-based L3 | 2026-01-07 09:36 | MRS_20*